Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts

1. Medicaid funding serves 72 million, $900 billion annually, facing possible cuts. 2. Proposed 340B reforms may benefit biopharma by limiting drug discount eligibility. 3. BMY could see positive effects from 340B policy changes, per analyst's insights. 4. Medicaid changes could negatively impact biopharma companies reliant on Medicaid sales. 5. Uncertainty around healthcare reforms may lead to volatility in the sector.